A change in KRAS/MAPK signaling or a BRAF or KRAS gene mutation causes drug resistance in MEK1/2 inhibitors in cancer cells like colorectal cancer, ovarian cancer, and others [51, 52]. Here, KRAS is linked to ovarian carcinoma.